Researchers from the Center for Stem Cell Biology and Regenerative Medicine and the Department of Medicine at Thomas Jefferson University claim that a gene shown to play a role in the aging process appears to play a role in the regulation of the differentiation of embryonic stem cells.
In the study, published online in the journal Aging Cell, the researchers identified a protein interaction that controls the silencing of Oct4, a key transcription factor that is critical to ensuring that embryonic stem cells remain pluripotent. The protein, WRNp, is the product of a gene associated with Werner syndrome, an autosomal
Steven Goldman, M.D., Ph.D.
Scientists have created a way to isolate neural stem cells – cells that give rise to all the cell types of the brain – from human brain tissue with unprecedented precision, an important step toward developing new treatments for conditions of the nervous system, like Parkinson’s and Huntington’s diseases and spinal cord injury.
The work by a team of neuroscientists at the University of Rochester Medical Center was published in the Nov. 3 issue of the Journal of Neuroscience. Neurologist Steven Goldman, M.D., Ph.D., chair of the Department of Neurology, led the
“Now that we have identified SOX10 as an initiator of myelination, we can work on developing a viral or pharmaceutical approach to inducing it in MS patients,” says Fraser J. Sim, PhD, assistant professor and senior author of the paper.
Transcription factors are proteins or molecules that bind to DNA and alter which genes are turned on, or expressed.
“If we could create a drug that would switch on SOX10, that would be therapeutically important,” Sim explains.
Removing Barriers to MS Stem Cell Therapy
Targeting SOX10 offers hope for a viable stem cell treatment for MS.
Long seen as having dramatic potential for treating
From left to right: A normal pig heart, a pig heart after being decellularised, the pig heart prepared for recellularisation. Photos courtesy of the University of Minnesota.
In a medical first, University researchers have created a beating heart in the laboratory. Using detergents, they stripped away the cells from rat hearts until only the nonliving matrix, or “skeleton,” was left; they then repopulated the matrix with fresh heart cells.
If perfected, the technique may be used someday to generate new hearts for patients. In the United States alone, about 5 million people live with heart failure, 550,000 new cases are
Monash University researchers are shedding light on the complex processes that underpin the creation and differentiation of stem cells, bringing closer the promise of ‘miracle’ therapies.
Dr Jose Polo of the Australian Regenerative Medicine Institute (ARMI) and the Department of Anatomy and Developmental Biology and his team, with collaborators at Harvard, have comprehensively mapped, for the first time, the process by which mature cells are re-programmed to become an induced pluripotent stem (iPS) cell.
iPS cells behave almost exactly like embryonic stem cells – they can become any cell in the body – but come without the ethical and scientific pitfalls.